Cancer Gene Therapy
Introgen Obtains Exclusive US Patent for Development of Adenoviral Vector Based Gene Therapies
Published in Gene Therapy Weekly, August 2nd, 2007
Introgen Therapeutics, Inc. (NASDAQ:INGN) announced that a patent has been awarded titled "Diminishing Viral Gene Expression by Promoter Replacement" by the U.S. Patent and Trademark Office focusing on adenoviral vector development, which is the most commercially important type of viral vector used in the field of gene therapy. The patent, U.S. Patent No 7,244,617, is one of numerous patents, pending or issued, that Introgen has licensed exclusively from The University of Texas System M. D. Anderson Cancer Center.
David L. Parker, Ph.D, J.D., Introgen's senior vice president of Intellectual Property, commented, "This patent is a significant addition to Introgen's...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-08-02)
More Articles from Gene Therapy Weekly
- Gene Therapy
One Man's Junk May be a Genomic Treasure - Gene Therapy
FDA Grants Fast Track Designation to Cardium's Phase 3 Angiogenic Gene Therapy for Heart Disease - Gene Therapy
Gene Discovered for Type 1 Diabetes in Children - Gene Therapy
Gene Identified for Crohn's Disease in Children - Gene Therapy
Oncology Supportive Care Market to See a Slight Growth to $14,679m in 2016 - Liver Cancer
ProlarixTM dose selected for phase 2 liver cancer study - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
